

Deliverable 22

Evaluation of options for implementing a pan-European regulatory system for macrobial BCAs

REBECA

Regulation of Biological Control Agents

Specific Support Action

Project no. SSPE-CT-2005-022709

Contract Start Date: 01-06-2006

Duration: 24 months

Project Coordinator: Ralf-Udo Ehlers, Christian-Albrechts-University of Kiel.

Document Classification

Title	Evaluation of options for implementing a pan-European regulatory system
Deliverable	22
Reporting Period	2
Contractual Date of Delivery	
Actual Date of Delivery	

Authors	Jeffery Bale
Work package	WP5
Dissemination	Public
Nature	Report
Version	01.00 Final
Keywords	macrobiols, invertebrates, biological control, regulation, implementation

Document History

All of the discussions and recommendations concerning macrobial (invertebrate) biological control agents were contained within REBECA Work Package 5 (WP5) and channelled into 5 deliverables (D19 to D23) as set out in the original proposal. These deliverables are in some cases closely interrelated e.g. D21 concerning the criteria for inclusion of species on a 'Positive list' (and how this could be managed), and this deliverable (D22) that evaluates options on how a regulatory system could implemented at a pan-European level.

The development and final agreement on the content of this and other WP5 deliverables relating to macrobial biocontrol agents were achieved via a workshop in Wageningen (The Netherlands) in April 2006, a conference in Salzau (Germany) in September 2006, a series of small group meetings on specific topics in the early part of 2007, a second workshop in Frankfurt (Germany) in July 2007, and the final conference in Brussels (Belgium) in September 2007.

During the course of the REBECA project it was recognised that the concept of a 'hierarchical regulatory system' was inextricably linked to the environmental risk assessment (ERA) of candidate biological control agents, and that for this reason it would be desirable to integrate this information, and produce a standardised 'Application Form for a Release Permit (Licence)' that could be used by all EU member states. As a further development, it was also recognized that it would be helpful to both regulators and industry for the application form to be accompanied by a 'Guidance Document', explaining in detail the information required in each section of the application form, which would constitute the submitted dossier. As such, whilst

the production of this standardized application form and accompanying guidance document are not specific deliverables as set out in the original submission, they are among the most important outputs of WP5, and an essential requirement for the implementation of a pan-European regulatory system. For this reason, the documents comprising the Application Form, Guidance Document, and Recommendations on ERA Methods (attached as Appendices 1, 2 and 3 to this deliverable) should be viewed as an integrated package.

A separate deliverable (D21) reviews the criteria for inclusion of macrobial biocontrol agents on a 'Positive List' of 'safe' species. The report on D21 makes reference to how the Positive List (originally produced by EPPO) could be managed in the future, and the arising recommendations are relevant to this deliverable, which is primarily concerned with the regulatory process that is applied to non-native species being considered for first use in a European country; for this reason, the 'Positive List' working group report is attached to this deliverable as Appendix 4.

Document Abstract

Regulation of macrobial biocontrol agents across Europe is patchy, with well organized systems in some EU countries, and no regulation in others. Whilst this situation allows biocontrol in some countries 'without restriction', it also has some disadvantages, most notably, the inability to prevent the spread of potentially harmful species to countries where they were never licensed for release; additionally, the lack of any consistency in the information requirements in those countries with regulation requires industry to prepare separate dossiers for each country. In the absence of any EU directive for macrobial agents, it is evident that any pan-European system has to operate on a voluntary basis. With this in mind, REBECA recommends that an Expert Group could provide valuable advice on the safety of release of novel agents to countries both with and without existing national regulatory systems – and achievement of this goal would be greatly aided by the Europe-wide adoption of the standardized 'Dossier Application Form', 'Guidance Document' and 'ERA Methods' produced by REBECA (Appendices 1-3 of this deliverable). It would be desirable for the Expert Group to be coordinated by an organization based in Europe and with an international reputation. REBECA therefore supports the initiative of EPPO and IOBC to form a joint Expert Group. Further, the success of the proposed regulatory system would be aided by other developments, including, the piloting of the new documentation in some member states, the translation of the documents into national languages, and a forum for the communication of information between regulators in different EU countries.

Table of contents

Introduction	5
Production of documentation	6
Coordination of a voluntary system	6
Evaluation of options on implementation of a balanced regulatory system	7
Implementation beyond REBECA	8
Piloting of forms in member states	8
Translation into other EU languages	9
Regulator contacts	9
Changing personnel	9
Applications made to other EU countries	10
Conclusions	10
References	10
Appendix 1: Application Form	11
Appendix 2: Guidance Document	22
Appendix 3: Report of Small Group Meeting on ‘Methods for Environmental Risk Assessment’ held in Rotterdam on March 29-30, 2007	32
Appendix A: Recommendations for regulation requirements for entomopathogenic nematodes	43
Appendix 4: Report from Small Group Meeting on current and future use of the EPPO List for IBCAs, held at CABI Europe-Switzerland, Delémont, Switzerland, March 11-12, 2007	49

Introduction

The use of invertebrate biocontrol agents (IBCA) in Europe is not regulated by any EU directive such as EU Council Directive 91/414/EEC that regulates the use of microorganisms, botanical substances and semiochemicals as plant protection products. As a result, there is a 'patchwork of regulation' of IBAs across Europe, in which some countries have strict controls on the import of non-native species enshrined in national legislation, and other countries, sometimes directly neighbouring countries, have no restrictions on the import and release of so-called 'exotic species'. As insects used in biocontrol are sometimes highly mobile, it is possible, perhaps likely, that an organism will migrate from a country where it has been released without regulation to a different country where its import and release would have been prohibited.

The absence of any EU-wide regulation of non-native IBAs can be viewed as having both advantages and disadvantages. As an example, the absence of regulation has been cited as one of the main reasons for the success of IBA-based biocontrol in Europe, and it is the case that there have been relatively few reports of any negative environmental effects arising from such unregulated releases. By contrast, the fact that countries with regulation have different 'information requirements' within their permit application forms means that companies have to produce separate dossiers for each country to which an application is made. Additionally, the recent rapid spread through Europe of the predatory ladybird *Harmonia axyridis* and concerns about possible local declines in native coccinellid populations has raised awareness among regulators, the biocontrol industry and governmental and NGOs responsible for environmental protection of the need to ensure the safe release of non-native species.

Prior to the REBECA project, various organizations (FAO, EPPO, OECD) had produced recommendations and guidelines on the environmental risk assessment (ERA) of non-native biocontrol agents. The content of these documents was then reviewed by the IOBC-WPRS 'Commission on the harmonization of invertebrate biological control agents' (CHIBCA), which produced an updated review 'Guidelines on Information Requirements for Import and Release of Invertebrate Biological Control Agents in European Countries', published in *Biocontrol News and Information* (Bigler *et al.*, 2005). Most of the regulators, representatives of industry and scientists who had contributed to the CHIBCA review became participants in the REBECA project, thus providing a continuity of knowledge.

Production of documentation

As a direct result of the REBECA Action, a standardised 'Dossier Application Form' is available for use by member states (see Appendix 1 of this report). This form is a distillation of all previous guidelines (FAO, EPPO, OECD), and translates the content of the Bigler *et al.*, (2005) publication into a structured document. This Application Form is accompanied by a 'Guidance Document' (Appendix 2) that provides clear guidance on the information that should be supplied in each section of the Application Form. One of the most important considerations in the evaluation of a non-native biocontrol agent is the assessment of environmental risks. Whilst regulators and the biocontrol industry have been aware of the risks that should be evaluated (establishment in country/area of release, effects on non-target species), there has been no clear statement or consensus on the methods by which data for ERA should be acquired, when information is not available in the published literature. The REBECA Action has rectified this problem by producing a set of recommended methods for data acquisition on establishment, host range and dispersal on insects and mites, and if necessary, for entomopathogenic nematodes (Appendix 3). It is the view of the REBECA Action that member state regulators and the biocontrol industry would benefit from using the same 'Dossier Application Form'. Against this background, the Frankfurt workshop and Brussels Conference reviewed options on how an EU-wide approach might be implemented.

Coordination of a voluntary system

During the course of the REBECA Action representatives of DG SANCO expressed the view that the EC had no plans to regulate the use of microbial biocontrol agents via a new directive. This in turn confirmed the notion that any coordination of regulation between member states would have to be achieved on a voluntary basis. Following the Salzau Conference in 2006, a working group was set up to review 'Current and future use of the EPPO Positive List for IBCAs'. The report from this group is attached as Appendix 4, and is discussed in detail in the report on D21. One of the main recommendations from this working group was that the current Positive List should be reviewed and updated by an Expert Group; furthermore, it was also recommended that the same Expert Group could provide advice on the environmental risks of 'new' IBCAs, to member states that have no current regulation or expertise in biocontrol, and to countries with regulation that may wish to seek advice on dossiers from the Expert Group. In effect, this expert group would therefore have a dual function, providing 'non-binding' advice on both the safety of new releases and the transfer of existing agents to the Positive List.

Evaluation of options on implementation of a balanced regulatory system

The options by which to achieve the implementation of the proposed regulatory system and hierarchical ERA were discussed at the Frankfurt workshop and Brussels Conference. It was noted that the envisaged regulatory system and ERA referred primarily to company dossiers seeking the first release in a European country of a non-native biocontrol agent, or in a second and subsequent countries. However, the REBECA report on the 'Positive List' (see Appendix 4) contained recommendations not only on how an Expert Group might function and under whose authority it would operate, but also on the idea of extending the remit of the Group to provide advice to member states (especially those without regulation or regulators) on applications for the first release of non-native microbial agents. Furthermore, it was reported in Frankfurt and Brussels that the Director General of EPPO had recently contacted the REBECA coordinator to confirm that EPPO intended to reactivate its interest in the Positive List and would collaborate with the IOBC (WPRS) to create a new Expert Group for this purpose.

A study carried out as part of the REBECA project reviewing regulation of invertebrate biological control agents in Australia, New Zealand, Canada and the USA (Hunt et al., 2007) also proposed that an Expert Panel be established and placed under the jurisdiction of the EU or an 'EU governmental body'. Under this scheme, the Expert Panel would review 'first release applications' received by the EU administrative body and provide a recommendation on release approval. The final decision would then be made by representatives on the EU administrative body.

The concept of EU-level regulation for microbial agents was discussed in detail in Frankfurt and some support was shown for the proposal. Advantageous features of this approach are that all countries would be aware of which species had been authorised for release and where, and there could be 'mutual recognition' between countries of safe releases. It would also ensure a harmonized process of invertebrate biological control agent regulation across all European member states. However, a number of concerns were also expressed about this system: (i) the EU through SANCO had previously indicated that it had no desire to regulate invertebrate biocontrol agents, and (ii) the establishment of an Agency might require legislation, and therefore would take 5-10 years to achieve.

Another major concern was that there was no guarantee that the Agency or Expert Group would accept the REBECA recommendations contained in the Guidance, ERA and Positive List documents as the basis for its assessments. It was also acknowledged that irrespective of the locality of a release, non-native species were likely to be transported 'across Europe' through international trade, and no system of licensing or legislation (member state or pan-European) could prevent this. However, with an EU-level system of regulation, representatives from neighbouring countries

would be able to participate in final decisions on release approvals, and issues of border-crossing by invertebrate biological control agents could be raised and incorporated into the decision-making process at this stage.

After detailed consideration of the options, the Frankfurt workshop supported the conclusion contained in the Positive List discussion document (Appendix 4) that there would be difficulty in achieving the objective of an Expert Group organized and coordinated by the EU. Further, the workshop made the 'pragmatic' recommendation that the EPPO-IOBC collaboration and Expert Group should be supported because (i) it could be developed in the near future, and (ii) whilst its advice was non-binding, if the aforementioned Dossier Application Form (Appendix 1), Guidance Document (Appendix 2) and 'ERA Methods' (Appendix 3) became 'EPPO Technical Reports', they would be distributed to all EU member states within the EPPO region. Whilst the EPPO-IOBC Expert Group was currently being set up to review and update the Positive List, there was strong support for it to take on the additional role of providing advice to member states on first release permit applications. This view was endorsed by the WP5 workshop at the Brussels conference. A schematic description of an EPPO-IOBC Expert Group with this dual function is shown in Figure 1, indicating its lines of communication with National Competent Authorities on new applications, and with EPPO with regard to the Positive List.

Implementation beyond REBECA

The Brussels conference considered additional steps that could be taken to aid a 'Europe-wide' adoption of the 'Dossier Application form' and related documents. A number of positive ideas emanated from this discussion and are summarized below.

Piloting of forms in member states

It was recommended that countries with regulation and which received applications for new species on a regular basis should adopt the standard 'Dossier Application form' for routine use and disseminate experience to other countries.




Figure 1: Schematic description of the role and lines of communication between an Expert Group, international organizations (EPPO-IOBC) and national competent authorities.

Translation into other EU languages

Views were expressed that take up of the new form and related documents would be much more likely if they were translated into national languages

Regulator contacts

It was acknowledged that because of the patchy nature of macrobial agents in Europe (unlike the microbial agents under EU directive 91/414), there was no network and little or contact between people responsible for the regulation of invertebrate BCAs in different EU countries. It was concluded that companies had the most up to date lists of 'national regulators' and this would enable compilation of list that could then be distributed to all member states.

Changing personnel

A common problem experienced by industry was that the person responsible for macrobial regulation in individual countries changed at regular intervals and the identity of the 'new' people was not communicated to industry or to other countries. It was suggested that each country could set up a generic website (non-native

licensing@), enabling all electronic documentation to reach its intended recipient and office, even if individual personnel had changed.

Applications made to other EU countries

A further problem arising from the absence of a communication network between macrobial regulators in different EU countries was the lack of information available to a regulator on organisms for which licence applications had been previously submitted to other member states and the outcome of the submissions. It was proposed that disclosure of this information could be a requirement in the Dossier Application form, enabling a regulator to discuss an application with their counterparts in other countries.

Conclusions

Regulation of macrobial biocontrol agents across Europe is patchy, with well organized systems in some EU countries, and no regulation in others. Whilst this situation allows biocontrol in some countries 'without restriction', it also has some disadvantages, most notably, the inability to prevent the spread of potentially harmful species to countries where they were never licensed for release; additionally, the lack of any consistency in the information requirements in those countries with regulation requires industry to prepare separate dossiers for submission to different countries. Overall, it would be beneficial to industry and to the reputation of biocontrol to have a consistent and coordinated framework of regulation across Europe. In absence of an EU directive, any pan-European regulatory system has to operate on a voluntary basis. The REBECA Action has produced documents (see Appendix 1-3) that have been designed for immediate introduction and will provide necessary consistency in regulatory practice between EU member states. After an analysis of options for implementation, REBECA recommends that an Expert Group formed from a link between EPPO and the IOBC can provide 'on request' expertise and advice on the safety of novel agents to countries both with and without national regulation. This 'service' would benefit from other developments, including the translation of the 'Dossier Application Form' and other documents into national languages, and mechanisms to facilitate communication between regulators in different EU countries with responsibility for administering the non-native biocontrol system.

References

Hunt, E.J., Kuhlmann, U., Sheppard, A., Qin, T.-K., Barratt, B.I.P., Harrison, L., Mason, P.G., Parker, D., Flanders, R.V. and Goolsby, J. Review of invertebrate biological control agent regulation in Australia, New Zealand, Canada and the USA: recommendations for a harmonized European system. *Journal of Applied Entomology*, in press.

Appendix 1: Application Form

Participants: A.J.M. Loomans^{*a}, F. Bigler^b, G. Sterk^c, J.S. Bale^d

^a*Plant Protection Service, P. O. Box 9102, 6700 HC Wageningen, The Netherlands*

^b*Agroscope FAL Reckenholz, Swiss Federal Research Station for Agroecology and Agriculture, 8046
Zürich, Switzerland*

^c*Biobest N.V., Ilse Velden 18, B-2260 Westerlo, Belgium*

^d*University of Birmingham, Edgbaston, Birmingham B15 2TT, UK*

^{*}**Author for correspondence: a.j.m.loomans@minlnv.nl**

Application form for the import, shipment, rearing and release of invertebrate biological control agents in European countries¹

Using this form

This form should be used for the submission of an application to a National Competent Authority (NCA) of the European Union (EU) for a permit to license the import for research, mass-rearing and/or release of an invertebrate natural enemy used for the biological control of invertebrate and plant pests (Invertebrate Biological Control Agent or IBCA) and for other beneficial organisms. Organisms include invertebrates as well as entomopathogenic nematodes², but not micro-organisms. Guidance on the completion of this form is provided in the accompanying Guidance Document¹. This form is valid for an application relating to a single biological control organism. An organism is characterised as any identifiable and recognisable taxon of the IBCA, either a species, or recognised sub-species, population, strain or biotype.

After the NCA has received your application (administrative forms and documentation/dossier), you will receive an acknowledgement of receipt within a specified period of time. The application will then be checked for completeness and subjected to a risk assessment in relation to the purpose of your application (e.g. for research under quarantine conditions, or a commercial release). The risk analysis will be conducted by the NCA or – upon its request – by a specified expert or group of experts. The NCA will conduct a risk analysis in the light of the information provided, or any other sources they have available. The NCA may need to contact you to clarify parts of the application or to seek further information. At all times and in all communication, including that with external experts, your application will be regarded as confidential. After the risk assessment has been completed, the NCA will make a decision as to whether to grant a permit within a previously agreed period of time. The licence to permit an import and/or release will be valid for a fixed period of time, assigned by the NCA, after which a renewal may be sought, or a request may be made to place the organism on the EPPO Positive List. In the case of mixed products, an application should be made for each separate component.

Information required to complete this form

This application form and related information requirements for the release of non-indigenous IBCAs contains 5 parts (numbered 1-5) and is structured in a step-wise way: depending on the origin of the organism and the purpose of the application, the sequence of assessments and level of information required is related to the perceived level of risk. An application for any specified organism should include the following information:

Part 1. Application information

A. Information on the applicant

B. Purpose of the application and use

Part 2. Information for indigenous and non-indigenous IBCAs

¹ Guidance on the completion of this Application form is provided in a separate document – Appendix 2.

² See REBECA WP 5 – Recommendations for regulation requirements for entomopathogenic nematodes

A. Taxonomy and origin

B. Product information

Where an application is made for the import for research and rearing of a non-indigenous species and/or release of a native IBCA, the applicant should proceed to sections 4 and 5 of the form. Where the application is for the release of a non-indigenous IBCA, section 3 of this form must be completed.

Part 3. Information requirements intentional release of a non-indigenous IBCA with reference to:

A. Biology and ecology

B. Assessment of risks and benefits

- a. Establishment,
- b. Host specificity
- c. Dispersal
- d. Direct and indirect effects

Part 4.
forms and Signature

Submission of

A. Submission details

B. Agreement: safeguards and signature

Part 5.

Appendices

Sections of the form to be completed

This form can be used for the import and release of all IBCAs. Depending on the purposes of use, either some or all parts of the form must to be completed.

- | | |
|--------------------------------------|------------------------|
| 1. Renewal of a previous application | parts 1, 4 and 5 |
| 2. First application | |
| • Organism on Positive List | parts 1, 2, 4 and 5 |
| • Import only | parts 1, 2, 4 and 5 |
| • Release of indigenous IBCAs | parts 1, 2, 4 and 5 |
| • Release of non-indigenous IBCAs | parts 1, 2, 3, 4 and 5 |

For more information: Call... or refer to our website..... or consult the Guidance Document

Part I. Application Information

A Information on the Applicant		
<p>1.1 Who will apply for the permit?</p> <p>*only a legally authorized person is allowed to apply.</p> <p>Include confirmation of the person's authorization and a copy of a valid identification card with the application.</p>	Name of organisation	
	Name of applicant*	
	Affiliation of applicant	
	Address	
	Postal code	
	City	
	Phone	
	Fax	
	E-mail	
	Chamber of Commerce #	
<p>1.2. Who is the contact person?</p> <p>Contact person, research manager and/or quarantine officer.</p>	Name of contact person	
	Affiliation of contact person	
	Visiting Address	
	Postal code	
	City	
	Phone	
	Fax	
	E-mail	

B Purpose of Application and Use

1.3. Information on application	Application type	Renewal <input type="checkbox"/>	First Application <input type="checkbox"/>
	Renewal (application number and expiry date)		
	Positive List organism	Yes <input type="checkbox"/>	No <input type="checkbox"/>
	Relation with previous/other applications		
	Application or registration elsewhere in Europe		
	Licence period requested	Mm/dd/year	
1.4. Purpose of use *To include full scale release of a classical biocontrol agent	Import	Research <input type="checkbox"/>	(Mass) rearing <input type="checkbox"/>
	Release	Trials <input type="checkbox"/>	Commercial* <input type="checkbox"/>
	Type of biocontrol programme		
	Area of release		
1.5. Facilities and procedures Describe how the risks, and the extent or probability of escape into the wild will be managed (for import/rearing of non-indigenous organisms only)	Address		
	Postal Code		
	Location		
	Facility		
	Contingency plan		
	Standard Operating Procedures		
	Quality control management		
	Accreditation		
1.6. Information on target organism(s) Give a description of the biology and ecology of the target pest(s), including weeds	Target host taxon		
	Names of target pests		
	Original area of distribution of the pests		
	Biology of pests		
	Target crops		

Part 2. Information for indigenous and non-indigenous IBCAs

A Taxonomy and Origin

2.1. Identity For what species/organism is the application made? Indicate which species is involved (a single species per application) and full scientific name and taxonomy	Class		
	Order		
	Family		
	Genus		
	Species		
	Sub-species		
	Common names		
	Alternative names		
	Associated organisms		
ID-Confirmation Indicate means, methods of ID-confirmation and vouchers.	Authority		
	Methodology		
	Voucher deposits		
2.2. Characterization of IBCA Specify life-stages, strains or taxonomic constraints	Diagnostic descriptions		
	Specific characteristics		
	Taxonomic characteristics		
2.3. Origin and Distribution IBCA What is the immediate source of the organism. Include details of the origin and distribution of the IBCA (species or lower taxon)	Origin	Indigenous <input type="checkbox"/>	Non-indigenous <input type="checkbox"/>
	Field collected		
	Laboratory culture		
	Producer/Supplier		
	Original area and distribution		
	Areas introduced before		

B Product Information

2.4. Product Information	Product	Product/Trade name	
		Producer/Supplier	
		Method of supply	
		Life stages	
		Label information	
		Storage	
		Method of use	
2.5. Product Composition	Product	Co-formulants	
		Contaminants	

In the case of a renewal of a previously successful application (section 1.3), or if the species or population is indigenous to the country or ecoregion, and/or imported for research or rearing only and/or is mentioned on the list of species considered safe for use in the intended area of release, no further information is required and only the submission details in 4A and B and Appendices (Part 5) need to be completed. For other applications, such as the release of a non-indigenous species, the information requirements in Part 3 must be supplied.

Part 3. Information requirements for intentional release of a non-indigenous IBCA

A Biology and Ecology

3.1. Information on Biology and Ecology Give a description of the biology and ecology of the IBCA	Life cycle – generations/year	
	Developmental biology	
	Mechanisms of survival	
	Mechanisms of dispersal	
	Climatic conditions	
	Habitat range	
	Host range	
	Natural enemies	

B Assessment of Risks and Benefits

3.2. Safety and Health Effects Potential hazards of IBCA, product or any co-formulants, and measures taken to limit operator exposure	Human health	
	Animal health	
	Measures of prevention	
3.3. Information on Environmental Risk Assessment (ERA) All fields should normally be completed (but see exemptions listed below), but may be weighted differently in the evaluation of risks	History of previous releases or introductions	
	Outcome of previous risk assessments	
3.3.1. Potential for establishment¹	Physical constraints	
	Resource constraints	
	Survival data and methods used	
	Evidence of establishment	
3.3.2. Host range assessment²	Wild hosts known	
	Organisms tested	

	Procedures used for host range testing	
	Target and non-target host plants	
3.3.3 Dispersal ³	Ability to disperse	
3.3.4. Direct and/or indirect non-target effects ⁴	Summary of available information and conclusions on risks	

¹ When outdoor establishment of the IBCA is very unlikely and predicted to die out rapidly (as indicated by the data provided), the subsequent fields need not be completed, and no further risk assessments are necessary;

² When outdoor establishment of the IBCA is necessary or likely to occur, host range information is essential for the risk assessment;

³ Dispersal test results are not required for glasshouse releases, but should be provided when IBCAs are released into open fields or structures that do not prevent escape (e.g. polytunnels) and long term establishment is very unlikely;

⁴ A summary of known direct and indirect non-target effects should always be given, irrespective of whether host range and/or dispersal have been assessed.

3.4. Efficacy and benefits of the IBCA Assessment of efficacy, economic and environmental benefits	Method(s) to determine efficacy	
	Results of efficacy trials	
	Economic benefits	
	Environmental benefits	

Part 4. Submission of forms and signature

A Submission Details		
4.1. Appendices Check for completeness of application	Information requirements	<input type="checkbox"/>
	Literature reference copies	<input type="checkbox"/>
	Identification of applicant	<input type="checkbox"/>
	Chamber of Commerce	<input type="checkbox"/>
	Authorization payment	<input type="checkbox"/>
4.2. Where to submit the application	Name organisation	
	Bureau	
	Address	
	Postal code	
	City	

B Agreement

4.3. General safeguards

The applicant or authorized user undertaking the release proceeds under the conditions of the authorization for release, taking into account of the following requirements:

- All appropriate safety procedures should be put in place.
- Any relevant information on adverse effects, which might relate to the released IBCA, should be reported immediately to the National Competent Authority (NCA).
- Information on sites and dates of supply or release of the IBCA should be made available to the NCA, if requested.
- Information requirements have been supplied according to the most recent knowledge, and that the conditions made by the NCA will be respected.

4.4. Signature* *completed by a legally authorized person	Date	
	Applicant's name	
	Signature	

Part 5. Appendices

Appendix 2: Guidance Document

Participants: A.J.M. Loomans^{*a}, F. Bigler^b, G. Sterk^c, J.S. Bale^d

^a*Plant Protection Service, P. O. Box 9102, 6700 HC Wageningen, The Netherlands*

^b*Agroscope FAL Reckenholz, Swiss Federal Research Station for Agroecology and Agriculture, 8046 Zürich, Switzerland*

^c*Biobest N.V., Ilse Velden 18, B-2260 Westerlo, Belgium*

^d*University of Birmingham, Edgbaston, Birmingham B15 2TT, UK*

*** Author for correspondence: a.j.m.loomans@minInv.nl**

Guidelines for the completion of an application for the import, shipment, rearing and release of invertebrate biological control agents in European countries³

Using this guidance

The purpose of this document is to provide guidance on how to complete the application form for a permit for the import (including labelling, packaging and storage in transit), mass-rearing and/or release of an Invertebrate Biological Control Agent (IBCA) and other beneficial organisms⁴. The application form and this accompanying guidance document are intended to cover all situations in which a permit (licence) is required: 1) for import and release, 2) for species and strains, 3) for different types of biological control programmes (augmentative, classical biocontrol, weeds) and includes, 4) product and efficacy information. The environmental risk assessment (ERA) and risk/benefit analysis will be based upon the information provided in the application form. It is therefore important that all required parts of the form are completed. It is also recommended that all EU countries should use the same application and guidance documents. The National Competent Authority (NCA) will conduct a risk analysis in the light of the information provided, or any other sources they have available. The dossier to be submitted to the NCA must include information on the organism⁵ (IBCA) for import (including shipment), research, rearing and/or release as specified in the following parts of the application form:

- Part 1. Information on the applicant (A) and purpose of the application and use (B)
- Part 2. Information on the invertebrate biological control agent: identity, specific characteristics, origin and distribution (A), and product information (B)
- Part 3. Information relating to intentional release of a non-indigenous IBCA: biology and ecology of the IBCA (A) and an assessment of risks and benefits of the release (B)
- Part 4. Information on where to send the application (A) and conditions (B)
- Part 5. Appendices

Parts 1-5 of this guidance document are divided into different sections and sub-sections. The title and number of each part, section and sub-section referred to in this document correspond with the same parts, sections and sub-sections of the application form. In the case of renewal of an application, parts

³These guidelines are largely based on Bigler, F., Bale, J.S., Cock, M.J.W., Dreyer, H., Greatrex, R., Kuhlmann, U., Loomans, A.J.M. and van Lenteren, J.C., 2005. Guidelines on information requirements for import and release of invertebrate biological control agents in European countries. *Biocontrol News and Information*, **26**: 115N-123N and redrafted during REBECA workshop discussions in 2005-2007.

⁴IPPC, 2005 - <http://www.ippc.int/>: Any organism directly or indirectly advantageous to plants or plant products, including biological control agents [ISPM No. 3, 2005, ISPM No. 5, 2007]

⁵Organism = any identifiable taxon of an IBCA; either a species, recognised sub-species, population, strain or biotype. Natural enemy = predator, parasitoid or EPN known to attack and develop on a certain host or prey and intended to be used for the biological control of certain plants, plant pests, stored products; IBCA = product of a certain specified natural enemy; non-indigenous = organism (taxon) originated and collected outside the area of release. For other terminology, the IPPC definitions are used.

1, 4 and 5 have to be completed. In the case of a first application, parts 1, 2, 4 and 5 must be completed by all applicants, including applications for the release of indigenous species, when required by the NCA. For applications to release a non-indigenous species, part 3 of the application form must also be completed.

Information to be submitted by the applicant

Part 1. Application information

A Information on the Applicant

Provide information (including contact details) on:

1.1 **Who will apply** for the permit⁶; include confirmation of the person's authorization and a copy of a valid identification card with the application.

1.2 **The contact person**, research manager and/or quarantine officer.

B Purpose of Application and Use

1.3. Information on the application:

- Indicate whether this is a first application or a renewal of a previous application. In the case of a renewal, include a dossier reference number and expiry date and highlight any changes introduced since the first application.
- Is the organism on the EPPO 'Positive List of IBCAs'⁷?
- Has an application for this organism been submitted elsewhere in Europe, or has the organism or a product containing the organism been registered elsewhere in Europe? Specify in what country and contact details, when the application was submitted and the outcome.
- Is there a relation with other applications currently submitted or previously licensed with other IBCAs or beneficial organism(s) in the same product?
- For what period is the permit requested (within the range allowed by the relevant NCA)?

1.4. Purpose of Use:

Indicate the purpose of the application and use of the organism:

- Indicate whether the application is made for (i) import for research and/or (mass) rearing or (ii) direct release⁸. Indicate whether a release is intended in the country of application or not;
- When releases are intended, indicate whether the applications are for trial purposes or for full field releases, in commercial and/or classical programmes;
- Type of biological control programme⁹: classical biological control (CBC), augmentative (inundative) biological control (IBC), weed biocontrol;

⁶ Only a legally authorized, registered person is allowed to apply.

⁷ EPPO (2002). *List of biological control agents widely used in the EPPO region*. EPPO Standard PM6/3(2). *EPPO Bulletin* **32**: 447–461. See full REBECA WP 5 report.

⁸ Release: intentional liberation of an IBCA into an ecosystem [see ISPM No. 3, 1996].

⁹ Eilenberg J. *et al.*, (2001). Suggestions for unifying the terminology in biological control. *Biocontrol* **46**: 387-400.

- For direct release in field trials or for commercial release, indicate whether permanent establishment is intended (classical release) or not (augmentative release);
- Provide details of area of application (e.g. protected, semi-protected glasshouse, open field, natural environment).

1.5. Facilities and Procedures

The research/production facilities and procedures: describe how the risks, and the extent or probability of escape into the wild will be managed (*for import of non-indigenous organisms only*). This can usually be done by means of one or more waivers.

- Address (physical), postal code, location (city);
- For imported material, provide details of labelling, packaging and storage during transit;
- Facility: describe the types of facilities used (greenhouses, laboratories, climate rooms or cabinets);
- Levels of containment: do you have a permit to work with quarantine organisms under the provisions of Directive EC/95/44¹⁰? If not, justify why the levels of containment proposed for transport, rearing or research are appropriate to avoid escape and spread; where feasible, a contingency plan to prevent undesired environmental effects should be provided.
- Quality control management system: give a description of the measures, methods and intervals to ensure quality and purity of the IBCA (species/strain), and methods for periodic control of purity and identity of mass-rearing, including Standard Operating Procedures for:
 - o Life stage and numbers (amount) to be imported;
 - o Methods and materials to be used for shipping (e.g. sealed container, host mummies, prey to be included, plant material included, etc.);
 - o Procedures to eliminate any contaminants of the imported agent that are of concern;
 - o Procedures to dispose of used research materials, including shipping materials;
 - o A plan for detecting escape and undesired environmental effects;
 - o Any other procedures specific to this importation (i.e. not part of standard procedures).
- Accreditation: is your organization certified and/or accredited for processes and/or activities (ISOs) as developed by the International Organization for Standardization¹¹. Relevant standards include ISO 9001 for 'Quality management' (general procedures) and ISO/IEC 17025 for 'General requirements for competence of test and calibration laboratories'. Provide details of the ISO standard(s) and activities for which you have certification and/or accreditation.

1.6. Information on the target organism(s) and area of application

- Name(s) of pest(s) to be controlled (order, family, genus, species and author), including weeds;
- Origin of the pest(s)/weeds and the natural occurrence in the area of release;
- Biology of pests: life cycle(s) of pests/weeds released against;
- Crops: damage inflicted on target crops or vegetation; crops or vegetation on which releases will be made.

¹⁰ Commission Directive 95/44/EC of 26 July 1995 establishing the conditions under which certain harmful organisms, plants, plant products and other objects listed in Annexes I to V to Council Directive 77/93/EEC may be introduced into or moved within the Community or certain protected zones thereof, for trial or scientific purposes and for work on varietal selections: see <http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:31995L0044:EN:HTML>

¹¹ For details, see <http://www.iso.org/iso/home.htm>

Part 2. Information for indigenous and non-indigenous IBCAs

A Taxonomy and origin

2.1. Identity and ID confirmation

For what species/organism is the application made? Indicate which species is involved (a single species per application) and full scientific name and taxonomy. Give an accurate identification of the IBCA or, where necessary, sufficient characterization to allow its unambiguous recognition, such as:

- Order, family, genus, species and author, and, where appropriate, sub-species, strain, or biotype; include common names and synonyms;
- Include the name of micro-organisms directly associated with the IBCA, e.g. identity of the symbiotic bacteria in entomopathogenic nematodes.

ID confirmation: Indicate means, methods of ID confirmation and vouchers:

- Authority: by which expert or institute has the organism been identified?
- By what method (morphological, molecular): if available, include a letter from a scientific expert, recognized by the NCA, stating the identity of the organism;
- Supply evidence of deposition of voucher specimens, with identity confirmed, in a recognized collection facility (these depositions must be made before the agent is released); include the name and location of institution(s) where voucher specimens are deposited;
- Where cultures are refreshed, confirmation of identity should be sought at regular intervals and additional vouchers should be deposited accordingly;
- Include the accurate identity of the symbiotic bacteria associated with entomopathogenic nematodes used as an IBCA.

2.2. Characterization of IBCA

Specify life-stages, strains or taxonomic constraints:

- General diagnostic descriptions of all life stages of the IBCA that are relevant for its use in biological control, highlighting details of any taxonomic characteristics and difficulties with the group (e.g. species complexes, cryptic species, poorly studied group);
- Describe specific characteristics of the species/strain(s) (where relevant), such as:
 - cold-hardiness (winter survival, diapausing abilities);
 - known pesticide resistance (if yes: what resistance);
 - information on differences from the parent wild strain.
- Where appropriate, molecular information (e.g. unique micro-satellite markers) used for diagnosis, especially for population identification, species complexes or cryptic species.

2.3. Origin and distribution

What is the immediate source of the organism. Include details of the origin and distribution of the IBCA (species or lower taxon) as follows:

a) Indicate whether indigenous or non-indigenous

b) If field collected, provide information on collection sites and dates, including:

- geographic area (approximate latitude, longitude and altitude of site);
- description of the original habitat(s) and host(s) from which the collection was made.

c) If from laboratory culture or production facility, provide information as indicated in (a) and in addition, the history of the culture stock, including:

- the immediate source of the organism (i.e. where it is produced), giving the name and address of the manufacturer, including the location of the production facility;
- any other source from which the culture has been collected or supplied;
- frequency and origin of additional wild stock used to refresh laboratory cultures.

d) Current distribution, including:

- Known areas of original natural distribution of the IBCA;
- Known areas where the IBCA has been intentionally or accidentally introduced.

B Product Information

2.4. Product information

For augmentative (inundative) commercial release or classical biocontrol, briefly describe the intended use and potential benefits that may be derived.

- Function of the IBCA (e.g. predator, parasitoid);
- Life stage(s) of the agent(s) to be released (e.g. pupae, adults);

For augmentative (inundative) commercial releases, the following information should be supplied:

- Trade name of the product;
- Method of supply and formulation (e.g. single species, interim prey, mixed species);
- Label and container information;
- Storage conditions (temperature, humidity, expiry date);
- Recommended method of use (e.g. frequency and dosage of release).

2.5. Product composition

Provide evidence that for inundative releases, the product is free from unwanted contaminants i.e. entomopathogens and hyperparasitoids, including:

- Co-formulants: give a description of co-formulants/organic contaminants included with the IBCA (e.g. plant material, live prey or other food materials, carrier material);
- Contaminants: give an assessment of the extent to which these should be of concern; frequency and percentage of hosts used in culture that might be present in the marketed product;
- Any combined or contaminant organism should be separately authorised before import and/or release.

In the case of a renewal of a previously successful application (section 1.3), or if the species or population is indigenous to the country or ecoregion, and/or imported for research or rearing only, and/or mentioned on the list of species considered safe for use in the intended area of release, no further information is required and only the submission details in Part 4A and B and Appendices (Part 5) need to be completed. For other applications, such as the release of a non-native species, the information requirements in Part 3 must be supplied.

Part 3. Information requirements for intentional release of a non-indigenous IBCA

A Biology and Ecology

3.1. Information on the biology and ecology (in current area of distribution)

Information provided below will be the main basis for the environmental risk assessment. Give a description of the biology and ecology of the IBCA, including:

- Life cycle and number of generations per year;
- information on developmental and reproductive biology (e.g. sexual/asexual reproduction, feeding and parasitisation habits, developmental period, reproductive potential, longevity);
- known mechanisms of survival of extreme conditions (e.g. diapause, quiescence, migration);
- known mechanisms of dispersal (e.g. flight capability, migratory behaviour);
- describe the climatic conditions of areas where the IBCA is known to be native and/or where it has established following intentional or accidental introductions;
- give information on the habitat range, including the habitat(s) where the IBCA is known to be native and/or where the IBCA is known to have established following intentional or accidental introductions (e.g. pasture, forest, scrub, etc) and known factors determining habitat selection (e.g. oviposition behaviour);
- Give details of natural enemies, including pathogens known to attack the IBCA.

B Assessment of Risks and Benefits

Information presented in this section forms the basis for the ERA. The ERA should address the whole country within which releases will be made, with reference to regional variation that may affect risk where appropriate. Information required in this section is considered essential to an ERA, and can be acquired from published literature, company reports and/or experimentation. Include details of previous risk assessments for the same species (strain/biotype) with outcomes and other relevant information, including the country of application. The submission of available and/or generated data and subsequent assessment of environmental risks follows a tiered approach: information should be acquired and risks assessed according to the hierarchical system proposed by Van Lenteren *et al.*, (2003)¹² and Van Lenteren *et al.*, (2006)¹³, and further updated in REBECA Work Package 5. When establishment of the IBCA is very unlikely and the organisms released are predicted to die out, the subsequent fields need not be filled in, and no further risk assessments are necessary; when establishment of the IBCA is likely or necessary (e.g. in classical control), host range information is a crucial requirement for risk assessment; dispersal test results are needed when IBCAs are released in

¹²van Lenteren, J.C., Babendreier, D., Bigler, F., Burgio, G., Hokkanen, H.M.T., Kuske, S., Loomans, A.J.M., Menzler-Hokkanen, I., van Rijn, P.C.J., Thomas, M.B., Tommasini, M.G. & Zeng, Q.Q. (2003) Environmental risk assessment of exotic natural enemies used in inundative biological control. *BioControl* **48**: 3–38.

¹³van Lenteren, J.C., Bale, J., Bigler, F., Hokkanen, H.M.T. & Loomans, A.J.M. (2006) Assessing risks of releasing exotic biological control agents of arthropod pests. *Annual Review of Entomology* **51**: 609–634.

open fields and establishment is very unlikely; a summary of known direct and indirect non-target effects should always be given.

3.2. Safety and Health Effects

Summarize available information on hazards to human, animal and plant health (for example, allergy, skin irritation, disease vectoring etc) by the IBCA, product or any co-formulants and measures taken to limit operator exposure, where necessary.

3.3. Information on Environmental Risk Assessment (ERA)

All fields should normally be completed (but see exemptions listed below), but may be weighted differently in the evaluation of risks. Summarize the history of previous releases or introductions and the outcome of previous risk assessments, with known consequences, including non-target effects.

3.3.1. Potential for establishment

Indicate any evidence of establishment as a result of previous releases or accidental introductions outside Europe or other IOBC/WPRS countries. Describe conditions (including extremes) affecting the IBCA's survival and reproduction in its current distribution.

Information on physical constraints, such as:

- Climatic similarities/differences between area of current distribution and area of intended release (e.g. temperature, altitude, humidity, day length, etc);
- Probability of temporary survival;
- Ability to survive and reproduce at temperatures and humidities outside the normal range (e.g. cold tolerance, overwintering ability); lower and upper temperature thresholds for development and survival; ability to enter diapause and/or overwinter (include test results);
- Other physiological and behavioural mechanisms for surviving extreme conditions;
- Dispersal potential (where known);

Information on resource constraints, such as:

- Availability and utilization of suitable hosts (target and non-target organisms) for short-term or long-term survival;
- Availability of suitable habitat, vegetation and plant food resources.

Indicate any evidence of establishment as a result of previous releases and/or accidental introductions outside Europe.

When outdoor establishment of the IBCA is very unlikely and the organisms released are predicted to die out rapidly, the subsequent fields need not be completed, and no further risk assessments will be necessary; when outdoor establishment of the IBCA is likely or necessary, host range information must be supplied.

3.3.2. Host range assessment

When establishment is likely and/or required, provide available information on recorded effects on non-target organisms, including:

- A list of known hosts other than the target pest(s) and potential of the IBCA to utilize non-target host organisms living on wild or cultivated plants;
- A list of non-target organisms that have previously been tested, including unrelated non-target hosts, including pollinators, and threatened and endangered species; indicate hosts that were not accepted in such tests;
- Procedures used to determine host range (e.g. phylogenetic relatedness, experimentation) and methods used for host-range testing (e.g. experimental design, test conditions, rearing methods for non-target species, life-stages tested etc);
- Possible direct effects on plants: describe possible direct effects of the IBCA on the host plant(s) of the target pest and on plant hosts of non-target species .

3.3.3. Dispersal

- Indicate potential direct (inundative) effects of mass-releases into open fields to neighbouring non-target hosts and habitats;

Direct effects of dispersal are considered for both indigenous and non-indigenous IBCAs where relevant to the direct environment of release. Dispersal test results are not required for glasshouse releases, but should be provided when IBCAs are released in open fields or structures that do not prevent escape (e.g. polytunnels) and long term establishment is very unlikely.

3.3.4. Additional information on direct and indirect non-target effects

Describe the history of previous releases or accidental introductions, with known consequences, including non-target effects. Indicate any other possible specific non-target effects, such as:

- Competition with, or displacement of, indigenous natural enemies in the area of intended release;
- Other constraints on the presence of natural enemies, including transfer of pathogens, of the released IBCA;
- Presence of natural enemies, including pathogens, that may affect establishment of the IBCA

A summary of known direct and indirect non-target effects should always be given, irrespective of whether host range and/or dispersal have been assessed. This section should also include conclusions on the risks associated with the intended release.

3.4. Efficacy and benefits of the IBCA and proposed release

Provide relevant information on:

- Anticipated contribution to the control of the target pest(s) and weeds;
- Estimated economic benefits (crop specific) of the IBCA;
- Possible environmental benefits, e.g. beneficial effects of release of the IBCA compared with current control methods;
- Method(s) to determine efficacy and, when required by the NCA, results of efficacy trials.

Part 4. Submission of forms and Signature

A Submission Details

4.1. Appendices

Check your application for completeness in the following areas:

- Information requirements (dossier)
- References, other literature and overview of information used in preparation of the dossier: include copies of relevant articles, chapters or reports in an appendix to the application documents;
- Identification of applicant: ID-card or passport;
- Chamber of Commerce copy;
- Authorization for payment of fees;
- Letter from a scientific expert, recognized by the NCA, confirming identity of the organism;
- Evidence of deposition of voucher specimens, with identity confirmed, in a recognized collection facility (these depositions must be made before the agent is released); include the name and location of institution(s) where voucher specimens are deposited
- In case of import for research and/or rearing, include a map of the facilities;
- Any other information that is relevant to the application.

4.2. Where to submit the application

Address details of the NCA

B Agreement

4.3. General safeguards

The applicant or authorized user undertaking the release proceeds under the conditions of the authorization for release, taking into account the following requirements:

- All appropriate safety procedures should be put in place.
- Any relevant information on adverse effects which might relate to the released IBCA should be reported immediately to the NCA.
- Information on sites and dates of supply or release of the IBCA should be made available to the NCA if requested.
- Information requirements have been supplied according to the most recent knowledge, and that the conditions made by the NCA will be respected.

4.4. Signature details

- Date
- Applicant's name
- Signature

All information and documents submitted for a licence application (dossier) will be regarded as 'commercial in confidence' by the NCA. The Environmental Risk Assessment and decision will be based on data and documents submitted for that specific licence application only.

Appendix 3: Report of Small Group Meeting on ‘Methods for Environmental Risk Assessment’ held in Rotterdam on March 29-30, 2007

revised after Frankfurt workshop, July 5-7, 2007, and confirmed at Brussels Conference, September 20-21, 2007. (This document also incorporates as an Appendix the recommendations of the Small Group Meeting on ‘Recommendations for regulation requirements for entomopathogenic nematodes’ held in Kiel on December 7-8, 2006, revised after the Frankfurt workshop, July 5-7, 2007, and confirmed at the Brussels Conference, September 20-21, 2007.)

In attendance: Jeff Bale (Chair), Martin Andermatt, Dirk Babendreier, Horst Bathon, Karel Bolckmans, Patrick De Clercq, Johannette Klapwijk, Antoon Loomans

General principles

1. Dossiers submitted for a licence/permit for a non-native biocontrol agent should include on optional basis, and where appropriate, information on the risks and benefits of the proposed release in comparison with alternative controls. Examples of relevant information might include a comparison with chemical control, or situations in which the target is a new exotic pest, and the alternative is a chemical that would undermine existing biocontrol schemes. Such information should be scientifically rigorous and evidence-based. Regulators are responsible for conducting the environmental risk assessment (ERA), which would include consideration of information provided on the wider risks and benefits of the release.
2. The preparation of a risk assessment dossier should be an interactive process between companies and regulators, in order that unnecessary and costly work is avoided, and that any studies that are conducted will meet the requirements of the regulatory authority.
3. The ERA guidelines should include inundative as well as classical biocontrol and be equally applicable to entomopathogenic nematodes (NB: in the context of this report, the term ‘inundative biocontrol’ is used synonymously with ‘augmentative control’, acknowledging that inundation is one form of augmentation). Whilst inundative control is currently the dominant method in Europe, the use of classical biocontrol may increase, hence the regulatory framework should be ‘fit for purpose’ for this development.
4. The ERA should be hierarchical (step-wise), enabling ‘safe’ and ‘risky’ species to be identified as quickly as possible to minimise costs, noting that the requirement

for specific tests and the order of testing are both flexible and case specific (see point 9).

- The hierarchical system proposed by van Lenteren *et al.*, (2003), and updated in van Lenteren *et al.*, (2006a, b) should be adopted with a clear definition of terms, and some minor modifications as summarised later in this report.

Definition of terms

- The term 'native' should be clearly defined in the context of biocontrol and ideally, this definition should be accepted by the regulatory authorities of all EU member states. A native species could be defined as 'naturally/originally' occurring in the country of intended release and neighbouring countries within the same climatic 'ecoregion'. This definition recognises that within continental Europe, national (political) boundaries do not prevent the movement of invertebrate organisms. This definition of 'native' would be beneficial to companies who wish to 'import' a species from one EU country to another (with similar climates), for which a licence may currently be required by some national regulatory bodies.
- The status of species that are 'naturalised' within one or more EU countries also requires definition and clarification with regard to the requirement for licensing, but 'naturalised' should not be interpreted as posing no risk.
- In the schematic ERA of van Lenteren *et al.*, (2006a) with sequential stages of assessment (establishment, host range and dispersal), it would be helpful to use the updated terms of 'Not Release', 'Release' and 'Proceed' as the three options that arise at each stage of the assessment. Specifically, 'Not Release' and 'Release' are preferable to 'No' and 'Yes', and the term 'Proceed' rather than 'On request', indicates the option for a company to continue the ERA to the next stage. The schematic ERA incorporating these terms is shown as Figure 1.




Figure 1: Flow chart summarising a hierarchical environmental risk assessment scheme for arthropod biocontrol agents (van Lenteren *et al.*, 2006).

Order of 'testing' in ERA

1. In most cases the ERA would follow the order of 'Establishment', 'Host Range' and 'Dispersal', though there are situations in which some of these assessments could be omitted, by-passed or conducted in a different order. As an example, a monophagous control agent for inundative biocontrol would not require an assessment of establishment, as any establishment would have minor or no impact on the wider ecosystem. For candidates for classical biocontrol, establishment is a requirement for success, so the first area of investigation would be host range.

Establishment

1. Long term establishment of a non-native species has two main requirements: (i) ability to survive in the climate in the area/country of release, and (ii) access to a food resource – usually, 'wild prey' (where 'prey' is synonymous with 'host') - which could include established 'exotic' species. It is recommended that both of these requirements are assessed (though not necessarily 'tested'), as this may identify some species that are 'climatically suited' for establishment but unable to establish because of the absence of any acceptable wild prey.
2. In general, an ability to diapause increases the likelihood of winter survival, and in turn, longer term establishment. For this reason, ability to diapause should be investigated as a matter of routine in inundative biocontrol, especially where source populations are collected from different countries or different regions within countries. Information on diapause may be available in the literature, or acquired by experimentation. Diapause induction stimuli vary between species but in most cases diapause can be induced by a 12:12 LD cycle at 15°C (and often by 12:12 LD at 20°C).

Key point: Ability to diapause should be assessed as a matter of routine prior to other 'tests' for establishment for species intended for inundative release (glasshouse or field), where an inability to diapause would be a desirable feature. Diapause studies are less important for classical control where establishment is normally a requirement for success.

3. Climatic suitability (most often, overwintering ability) can be assessed by the system developed by Bale and co-workers (Hatherly *et al.*, 2005) in which laboratory survival at 5°C is a reliable predictor of duration of field survival in winter, in northern European countries or regions with a winter climate similar to the UK. The system is now based on 7 (mainly predatory) species, which all

'conform' within a strongly correlated relationship. This approach enables species for inundative biocontrol to be categorised as 'safe' (die out within about 4 weeks of release), 'marginal' or 'likely to establish' (can survive for entire winter). Further analyses should be conducted to identify as far as possible 'survival time limits' for each category, and the extent of the ecoregion to which the data could be applied. Also, as most of the species examined so far are predators, further studies are required to assess the wider applicability of this system to parasitoids. As those species which 'die out quickly' are usually unable to survive below their developmental threshold (often in the range of 8-10°C for species of tropical origin), the developmental threshold might be an additional predictor of establishment. This could be investigated as the data are usually available in the literature, but some caution is required as reported thresholds may vary depending on regional variations in different source populations, stage specific differences, and differences related to different prey-host plant combinations used in experiments and in commercial production.

Key point: When experimental data on establishment are required, it is proposed that a laboratory assessment of survival at 5°C is appropriate to predict field survival, particularly for weakly cold tolerant species. Companies could usefully indicate to which countries or ecoregions such data would apply.

4. The species that pose interpretational difficulties are those in the 'marginal' zone that can survive for 1-2 months but not entire winters. For such species, it would be relatively easy to assess their acute lethal temperature and compare this with regularly occurring minimum temperatures in areas of intended release. However, as the effect of cold stress is determined by both the temperature and the duration of exposure, the reliability of this 'quick test' for 'marginal' species requires further evaluation.

Any 'climate survival' test should include different life cycle stages (unless there is a known overwintering stage), with and without an acclimation treatment, and where appropriate, with access to a food (prey) resource.

Key point: For species that are predicted (or shown) to die out after brief periods of winter low temperatures, no further risk assessments are necessary, other than a consideration of direct and indirect effects, as for a native species.

5. The second requirement for establishment is availability of one or more species of wild prey (which, depending on the climate, may be target or non-target species). The working group considered whether assessment of ability to feed on selected species of wild prey could form the basis of a preliminary 'test' of host range. To avoid confusion, it is recommended that the wild prey requirement for

establishment is kept distinct from host range testing. Therefore, in terms of completing a risk assessment for establishment, the ability of the candidate agent should be assessed on one, or a small number of commonly available wild prey that are phylogenetically related to the target species. With the benefit of experience it may be possible to produce a 'recommended list', but as an example, if the glasshouse target was a species of whitefly, then the cabbage whitefly *Aleyrodes proletella* would be an appropriate wild prey. It was acknowledged that for most non-native biocontrol agents there are likely to be suitable wild prey, but if a candidate species did not feed on one or more close relatives of the target, this might be an indication of host specificity, and would therefore be valuable information in the overall risk assessment. In this part of the establishment assay, the response of the control agent should be recorded in terms of attack (attempt to feed or oviposit), death of the prey, and ability of the agent to develop on the wild prey and produce reproductively viable adults.

Host range

6. The second aspect of risk assessment of inundatively released agents is host range, but this would be the first area of investigation for a classical control agent (see point 9). The meeting noted that there have been a number of studies and recommendations on host range testing. In general, the group recommend adoption of the testing scheme for arthropod biocontrol agents proposed by van Lenteren (2006b) and to select non-target species for host specificity testing as recommended by Kuhlmann *et al.*, (2006). Testing schemes for weed biocontrol have been reviewed by Sheppard *et al.*, (2005), and the selection of non-target species follows recommendations made by Wapshere (1974).

Key point: Species selected as 'test' prey and hosts are used to obtain an indication of the likely host range, not a precise list of non-target species that are accepted or rejected. For this reason, the selected list should be representative of different taxonomic groups rather than a particular country. Ideally, the same list, or at least a similar one, should be applicable across Europe.

7. It was recognised that host range testing could be an expensive exercise, beyond the financial limitations of even the largest companies. For this reason, it is proposed that host range testing should be conducted in two stages. It was felt unwise to be prescriptive about the exact number of species to be used in each stage, but typically this could be 3 species in stage 1 and a further 6 species in stage 2 of an arthropod biocontrol program. This would allow companies to decide at stage 1 whether to continue with further host range testing.

Key point: The identity and number of species to be included in host range tests should ideally be discussed with experts and agreed with the regulator prior to any experimentation.

Stage 1 assessment should include a phylogenetically close relative of the target prey or host (such as the species used in the establishment assay above), a second close relative, and a third species that is taxonomically distinct but commonly available outdoors, including during winter where appropriate to the seasonal biology of the agent. Data recorded should be attack, death of prey or host and development to adult as with the establishment assay.

8. Where the Stage 1 test indicates some level of specificity (e.g. only the phylogenetically related species are accepted as prey or hosts), it is recommended to proceed to stage 2 testing. For arthropod biocontrol, the working group endorsed the system proposed by Kuhlmann *et al.*, (2006) in which non-target species are selected from three categories: 1. Phylogenetically related; 2. Occurs in the same ecological niche; 3. Unrelated 'safeguard' species.
9. The working group was aware of a number of studies that have compared the physiological ('apparent') host range of some parasitoids, and the 'ecological' host range that is observed in nature. Invariably, laboratory assessments in which hosts are offered to natural enemies in 'no choice' tests overestimates the natural host range. The stepwise procedure proposed by Van Lenteren *et al.*, (2006b) is recommended as the method that should be used for arthropod biocontrol to make an estimation of the range of non-target species attacked under field conditions.

If the host/prey is accepted in the first two steps (conducted in small arenas), the step 3 test should be carried out in contained environments such as large cages, in which prey or hosts feed on growing plants and the agent is able to move freely around the cage. It is recommended that three treatments are compared with appropriate replication: 1. Target species alone (control); 2. Non-target alone; 3. Target and non-target together.

Key point: If acceptance of non-target hosts is observed in no-choice tests, a further test needs to include direct comparison of the acceptance and development on non-target species when the target species is simultaneously available.

Dispersal

10. In general, the need to assess dispersal will be restricted to a limited number of candidate agents for inundative biocontrol. If it is clear that a species can establish in the release environment, it should be assumed that dispersal will occur – the unknown factors being ‘how soon’ and ‘how far’, and these are both difficult to quantify on a ‘pan-European’ scale. However, there are circumstances in which dispersal may be limited (flightless species), and such information should be provided in a dossier.

Key point: Dispersal should not be tested in species that can establish in the release environment.

11. If no establishment is predicted, any effects on the wider environment will be transient and generally restricted to the ‘summer season’. It is recommended that dispersal should not be assessed in species that are used exclusively in glasshouses where any escapes will involve low numbers of individuals that will have minimal impact on the neighbouring species and ecosystem before they die out.

Key point: Dispersal should be tested only when agents are released into open fields or structures that do not restrict escape.

12. The impact of an ‘open field’ release where there is no prospect of survival through winter will depend on the numbers released and dispersal distances, and the proximity of the release area to sites of special scientific interest, such as nature reserves. Dispersal data are generally difficult to obtain but a description of methods by which to assess dispersal for inundatively released biological control agents is provided by Mills *et al.*, (2006). It is also recommended that a database of information should be created from the literature and experimental studies to provide ‘typical dispersal distances’ for different taxonomic groups commonly used in biocontrol. Companies should have the discretion to provide information on atypical species with limited dispersal ability.

Direct and indirect effects

13. Direct and indirect effects are a summary of information gained from the available literature. When such information is not readily available, these effects may be estimated by ‘expert knowledge’ or generated from the data on establishment, host range and dispersal in the ERA. Examples of direct effects would include effects on non-target species and on other trophic levels (such as intraguild predation and plant feeding damage), hybridization and enrichment and vectoring (van Lenteren *et al.*, 2003; Bigler *et al.*, 2006). Indirect effects are those that occur when there is no direct interaction between the control agent and non-target species, such as competition and competitive displacement (see van

Lenteren et al., 2003; Bigler et al., 2006). Indirect effects are difficult to quantify, but are likely to be related to the scale of the direct effects.

14. In situations where winter survival of the candidate agent for inundative biocontrol has been demonstrated in the establishment experiments (or seems likely to occur) and where the species is known or shown to be polyphagous, a company may decide that further investment in host range or other forms of testing would not be cost effective, as the dossier may not lead to a successful licence application. In such situations, a company could prepare a dossier describing a 'worst case scenario' that might arise from a release and provide relevant information for a 'risk-benefit' analysis compared with other available methods of control. In effect, although the biological control agent may pose some risk, this may be less than for other control options. The working group supported this approach, but were of the view that there may be difficulties in obtaining reliable comparative data for the alternative method(s) of control. The group noted however that there are examples of previously released species that have survived in the northern European climate, and are known to be polyphagous, but as yet, have not had any detectable impact on native species or ecosystems. A risk assessment for such species evaluated under current regulatory guidelines would almost certainly lead to a 'licence rejection' when considered in isolation, but the species might be the best option in comparative terms.

Key point: For polyphagous agents with establishment potential, companies should have the option to submit a dossier containing information on the risks and benefits of the proposed release compared with other possible controls. This information would be evaluated by the regulator as part of the ERA.

15. Direct and indirect effects of classical biological agents should be addressed in pre-release studies, because establishment of such species is essentially irreversible. Additionally, negative direct effects of classical biocontrol agents on non-target prey or hosts have become a major issue in this method of control.

Nematodes

16. It was a strong recommendation of the group that the proposed ERA should include entomopathogenic nematodes (EPNs), allowing for the development of appropriate methods and modification to the order of testing as appropriate. A separate working group reviewed ERA issues relating to EPNs and their report is attached as Appendix 1. The overall conclusions were that (i) EPNs have very limited potential to cause non-target effects and (ii) should be included within the same ERA framework that is applied to insects and mites, but with the recommendation that data on establishment, dispersal, host range and indirect

and direct effects would not normally be necessary because of the limited potential of EPNs to disperse or persist at the site of application. The remote risk related to the use of *Heterorhabditis indica* can be excluded by a precise identification of its associated symbiotic bacterium (see Appendix A of this document for full details).

Related issues:

Efficacy trials

17. It is likely that companies will want to carry out efficacy trials and ERA experiments simultaneously to minimize the time between product development and commercial release. Some of the efficacy work needs to be conducted under commercial or semi-commercial conditions (to determine effectiveness of agent on different crops, release rates etc), but this would pose some risk in species with the potential to establish. It was recommended that 'establishment potential' should be assessed before any commercial scale efficacy trials. In situations where there is no prospect of establishment in the local environment, companies should be able to conduct efficacy trials under outdoor or open field conditions. Where some establishment is possible or likely, the location and biosecurity of efficacy trials should be discussed with the regulator. As a general principle, companies should conduct such trials in a contained facility (large cage, glasshouse), taking all reasonable effort to prevent escape, in sites that are geographically isolated from areas of 'scientific sensitivity', and with regular monitoring in the immediate vicinity of the trial to detect any occurrence of the agent outside of the enclosed environment. When such escapes are observed, the trial should be terminated immediately and all plants and invertebrate material destroyed. Similarly, at the end of the trial, all plants and pests/control agents should be destroyed. These conditions should be applied to all researchers involved in biocontrol research, including universities and research institutes.

***Key point:* Establishment potential of inundative biocontrol agents should be assessed prior to commercial scale efficacy trials. For species with no ability to establish in the climatic area of the trial, experiments can be conducted under 'open field' conditions if appropriate. When establishment is possible or likely, an appropriate level of biosecurity should be adopted in discussion with the regulatory authority.**

18. In classical biocontrol programmes, information on the likely efficacy of a candidate agent should be collected in pre-release studies, because classical biocontrol agents that build up high densities in the introduced range but have no or minimal impact on the population dynamics of the target prey or host are

considered to pose a significant risk of indirect non-target effects (Pearson and Callaway 2003).

IPR and data protection

19. Across the spectrum of companies operating in Europe, there is a variable level of investment in R&D, with limited scope for such activity in small companies. There was concern expressed that some companies seemed able to obtain licences in some countries for species previously licensed to a different company, without undertaking an independent ERA, or demonstrating that the organism was of the same 'strain' or derived from the same source population as the 'first' application/release. The group were of the view that information submitted in a dossier was covered by data protection legislation and could not be copied without permission. Also, whilst the information could be divulged to people and organisations involved in the assessment and consultation of the dossier, this should not include a competitor company. It would be desirable for this issue to be discussed and resolved by the IBMA, but there are some steps that could be recommended by REBECA. Firstly, all information submitted in a risk assessment dossier should be regarded as 'Commercial in Confidence', with this statement clearly 'stamped' on the document. Secondly, if a company submits a licence application for a species previously licensed to a different company, the second and subsequent companies should verify that the ERA data have been independently acquired, or that the previous ERA is being submitted with the permission of the first company.

Expert Group

20. During the course of the meeting they were several areas of the ERA policy and methodology in which an 'Expert Group' would be able to construct general advice of benefit to companies and regulators: for example, species and taxonomic groups to be used in host range testing, creation of a 'dispersal database', appropriate levels of containment in commercial scale efficacy trials.

Key point: An Expert Group would be of benefit to companies and regulators in a range of areas relating to the content of dossiers and environmental risk assessment.

References

- Bigler, F., Babendreier, D. & Kuhlmann, U., Environmental Impact of Invertebrates for Biological Control of Arthropods. Methods and Risk Assessment, CABI Publishing, Wallingford, UK.

- Hatherly, I.S., Hart, A.J., Tullett, A.G.T. and Bale, J.S. (2005) Use of thermal data as a screen for the establishment potential of non-native biocontrol agents in the UK. *BioControl* **50**, 687-698.
- Kuhlmann, U. Schaffner, U. and Mason, P.G., 2006. Selection of non-target species for host specificity testing Pp. 15-37 in: Bigler, F., Babendreier, D. & Kuhlmann, U., *Environmental Impact of Invertebrates for Biological Control of Arthropods. Methods and Risk Assessment*, CABI Publishing, Wallingford, UK.
- Mills, N.J., Babendreier, D. and Loomans, A.J.M., 2006. Methods for monitoring the dispersal of natural enemies from point source releases associated with augmentative biological control. Pp. 114-121 in: Bigler, F., Babendreier, D. & Kuhlmann, U., *Environmental Impact of Invertebrates for Biological Control of Arthropods. Methods and Risk Assessment*, CABI Publishing, Wallingford, UK.
- Pearson, D.E. and Callaway, R.M. (2003) Indirect effects of host-specific biological control agents. *Trends Ecol. Evol.* **18**, 456–461.
- Sheppard, A.W., van Klinken, R.D., Heard, T.A. (2005) Scientific advances in the analysis of direct risks of weed biological control agents to nontarget plants. *Biological Control* **35**: 215-226.
- van Lenteren J.C., Babendreier, D., Bigler, F., Burgio, G., Hokkanen, H.M.T., Kuske, S., Loomans, A.J.M., Menzler-Hokkanen, I., van Rijn, P.C.J, Thomas, M.B., Tommasini, M.G. and Q.-Q. Zeng, 2003. Environmental risk assessment of exotic natural enemies used in inundative biological control. *BioControl* **48**, 3-38.
- van Lenteren, J.C., Bale, J.S., Bigler, F., Hokkanen, H.M.T. and Loomans, A.J.M. (2006a) Assessing risks of releasing exotic natural enemies of arthropod pests. *Annual Review of Entomology* **51**, 609-634.
- van Lenteren, J.C., Cock, M.J.W., Hoffmeister, T.S. and Sands, D.P.A., (2006b). Host specificity in arthropod biological control, methods for testing and interpretation of the data. Pp. 38-63 in : Bigler, F., Babendreier, D. & Kuhlmann, U., *Environmental Impact of Invertebrates for Biological Control of Arthropods. Methods and Risk Assessment*, CABI Publishing, Wallingford, UK.
- Wapshere, A. J. (1974) A strategy for evaluating the safety of organisms for biological weed control. *Annals of Applied Biology* **77**, 201-211.



Appendix A: Recommendations for regulation requirements for entomopathogenic nematodes

Participants: Ralf-Udo Ehlers^a, Olaf Strauch^a, Itamar Glazer^b

^a *Institute for Phytopathology, Dept. for Biotechnology and Biological Control, Christian-Albrechts-University Kiel, Hermann-Rodewald-Str.9, 24118 Kiel, Germany*

^b *Volcani Center, Institute of Plant Protection, Department of Nematology, P.O. Box 6, 50250 Bet Dagan, Israel*

**Author for correspondence: ehlers@biotec.uni-kiel.de
Recommendations for regulation requirements for entomopathogenic nematodes (EPNs)**

History

At the REBECA Conference in Salzau (September 2006), a working group was established to review environmental risk assessment (ERA) methods for EPNs, and to determine whether EPNs used in biological control could be regulated according to the guidelines developed for insects and mites. The working group met in Kiel, Germany on December 7-8, 2006. The document produced at this meeting was then sent to 65 European experts on entomopathogenic nematodes who had previously cooperated in the COST Action 850 "Biocontrol Symbiosis" network. The document was amended in the light of comments from these experts and then presented at the REBECA WP5 workshop held in Frankfurt on July 5-6, 2007. Further amendments were made according to comments received at the Frankfurt meeting and also at the Conference in Brussels on September 20-21, 2007. The final version of the recommendations is given below.

Recommendation on regulation data requirements

1. Prior to commercial use, nematodes must be identified accurately according to current state-of-the-art methods.
2. If the nematode under consideration is *Heterorhabditis indica*, the symbiotic bacteria must also be accurately identified, to exclude the possibility that the bacterium is *Photorhabdus asymbiotica*.
3. If the nematode species is indigenous to the country/region of intended release, no further data requirements are necessary.
4. When the nematode species is not indigenous to the intended country/region of release, voucher specimens should be deposited in a recognised nematode taxonomic collection.
5. For exotic nematodes species, details should be provided on the origin, known distribution and target host range

Justification

It is generally accepted that the use of exotic IBCAs should be regulated and this view has been endorsed by the REBECA Action. For the environmental risk assessment of insect and mite biocontrol agents, data on the establishment, host range and dispersal are normally required. During the REBECA Salzau Conference the nematologist participants were requested to establish a working group with the previously described remit. The conclusions of this working group are that (a) nematodes can be regulated within the same hierarchical ERA system developed for insects and mites, but (b) data on the host range, establishment and dispersal of EPNs would not normally be required.

1. Safety: Accumulated scientific data and activities of the OECD Cooperative Research Programme "Biological Resource Management for Sustainable Agriculture

Systems” (Theme 3: Utilisation and Ecology of New Organisms), and COST Actions 819 and 850 indicate that EPNs pose little or no risk to humans, vertebrates or the environment (e.g. Ehlers and Hokkanen ,1996; Barbercheck and Millar, 2000; Akhurst and Smith, 2002; Ehlers, 2003; www.cost850.ch).

2. Risk to human health: Entomopathogenic nematodes do not affect higher vertebrates such as rats, rabbits or monkeys (Bathon, 1996). EPNs carry symbiotic bacteria of the genera *Xenorhabdus* and *Photorhabdus*. However, humans are not usually exposed to these symbiotic bacteria as they can not survive outside the nematode or an insect host (Boemare 2002). In general, symbiotic bacteria of the genus *Xenorhabdus* associated with nematode species of the genus *Steinernema* have never been found in association with humans. The same is true for symbiotic bacteria of the genus *Photorhabdus* associated with nematodes of the genus *Heterorhabditis*, with one single exception: the emerging opportunistic pathogen *Photorhabdus asymbiotica*. In the past, this species has never been found in association with entomopathogenic nematodes. This bacterium was originally described from 5 clinical cases in the USA (Farmer et al., 1989) and another 5 in Australia (Peel et al., 1999). These isolates were assigned to the species *Photorhabdus asymbiotica* by Szállás et al. (1997) and Fischer-Le Saux et al. (1998). Other pathogenic bacteria were also found in these patients, leading to the view that *Photorhabdus asymbiotica* is an opportunistic bacterium. All bacterial infections responded to treatment with antibiotics, and importantly, no nematodes were found associated with either the USA or in all but one of Australian infections.

In one recent Australian case, an infection with *P. asymbiotica* could be related to the nematode *H. indica* (Gerrard et al. 2006). The patient had been digging fence post holes using his hand as a scoop. He had a history of minor skin trauma and subsequently developed an infection on his hand, from which *P. asymbiotica* was isolated. Gerrard et al. (2006) were able to isolate *H. indica* from the soil site where the patient had been digging. This case seems to be exceptional, as *H. indica* is normally associated with *P. luminescens* subsp. *akhurstii*, a species which has never been found in association with humans. All symbionts of the *H. indica* strains held in the large nematode collection at the INRA laboratory in Montpellier, France, belong to *P. luminescens* (Patrick Tailliez 2007, personal communication). It is therefore concluded that the association of *H. indica* with *P. asymbiotica* is extremely rare. *H. indica* is of tropical origin and has been used in the USA to control weevils on citrus for 10 years (Shapiro-Ilan et al., 2005) without any reported problems for producers or users. The US EPA does not regulate the use of EPNs (Ehlers, 2005). As a precaution, the use of the *H. indica* for biological control should be preceded by a precise identification of its symbiotic bacterium. Sequencing the 16S rDNA or gyrase sub-unit B genes and alignment with available data will enable the symbiotic bacterium to be accurately identified.

3. Non-target effects: Non-target effects of EPNs are limited to invertebrates. These risks are generally remote and transient in treated fields (e.g., Bathon, 1996; Lawrence et al., 2006) and limited to organisms living in the soil or other cryptic environments as EPNs desiccate on foliage (Glazer 2002) before they can cause major damage to non-target species. The host range of EPNs varies between species; some are highly specific (e.g. *S. scapterisci*) (Peters, 1996), whilst others have a wider host range (e.g. *S. carpocapsae*). Host range is often wide when tested in laboratory assays in Petri dishes, but more limited under natural conditions (Bathon, 1996). As the biological characteristics of EPNs lack major differences independent of species designation and origin, host range testing is not usually required for the use of exotic species in biological control (also because of their limited potential for establishment and dispersal).

4. Establishment and Dispersal: EPNs have the potential to establish after application, should sufficient target insects be present. When the target population has disappeared, EPNs cannot persist for more than a few months (e.g. Fitters & Griffin, 2006; Susurluk and Ehlers 2007; Smits, 1996). However, any establishment is highly localised around the area of application because of their limited potential to disperse (Lewis, 2002). Evidence for displacement of native species has not been found (Barbercheck and Millar, 2000).

5. Details on the origin, known distribution and target host range: Information from published literature or from the applicant is normally sufficient. Information on the origin and knowledge of its distribution will indicate whether the species is exotic. Information on the target to be controlled will indicate where the EPN will be used.

Conclusions

EPNs are generally regarded as biological control organisms with limited potential to cause non-target effects. The REBECA Action concluded that EPNs could be included within the same ERA framework that is applied to insects and mites but that data on establishment, dispersal, host range and indirect and direct effects would not normally be necessary because of the limited potential of EPNs to disperse or persist at the site of application. The remote risk related to the use of the species *Heterorhabditis indica* can be excluded by a precise identification of its symbiotic bacterium.

References

- Akhurst, R. and Smith, K. 2002. Regulation and Safety. In: R. Gaugler (ed.), Entomopathogenic Nematology. CABI Publishing, Wallingford, Oxon, UK, pp. 311-332.
- Boemare, N. 2002. Biology, taxonomy and systematics of *Photorhabdus* and *Xenorhabdus*. In: R. Gaugler (ed.), Entomopathogenic Nematology. CABI Publishing, Wallingford, Oxon, UK, pp. 35-56.
- Barbercheck, M.E. and Millar, L.C. 2000. Environmental impacts of entomopathogenic nematodes used for biological control in soil. In: P. A. Follett, J. J. Duan (eds.), Nontarget effects of biological control. Kluwer Academic Publishers, Dordrecht, NL, pp. 287-308.
- Bathon, H. 1996. Impact of entomopathogenic nematodes on non-target hosts. *Biocontrol Science and Technology*. 6, 421-434.
- Ehlers, R.-U. 2003: Biocontrol Nematodes In: H.M.T. Hokkanen & A.E. Hajek. Environmental Impacts of Microbial Insecticides – Need and Methods for Risk Assessment Kluwer Academic Publisher, Dordrecht, pp. 177-220.
- Ehlers, R.-U. 2005. Forum on Safety and Regulation 2005. In: P.S. Grewal, R.-U. Ehlers and D.I. Shapiro-Ilan (eds), Nematodes as biological control agents. CABI Publishing, Oxfordshire, UK. pp. 107-114.
- Ehlers, R.-U. and Hokkanen, H.M.T. 1996. Insect biocontrol with non-endemic entomopathogenic nematodes (*Steinernema* and *Heterorhabditis* spp.): Conclusions and recommendations of a combined OECD and COST workshop on scientific and regulatory policy issues. *Biocontrol Science and Technology*. 6, 295-302.
- Farmer III, J. J., J. H. Jörgensen, P. A. D. Grimont, R. J. Akhurst, G. O. Poinar Jr., E. Ageron, G. V. Pierce, J. A. Smith, G. P. Carter, K. L. Wilson and F. W. Hickman-Brenner. 1989. *Xenorhabdus luminescens* DNA hybridization group 5 from human clinical specimens. *J. Clin. Microbiol.* 27: 1594-1600.
- Fitters, P.F.L., Griffin, C.T. 2006. Survival, starvation, and activity in *Heterorhabditis megidis* (Nematoda: Heterorhabditidae). *Biological Control*. 37, 82-88.
- Gerrard, J.G., Joyce, S.A., Clarke, D.J., French-Constant, R.H., Nimmo, G.R., Looke, D.F.M., Feil, E.J., Pearce, L. and Waterfield, N.R. 2006. Nematode

- symbiont for *Photorhabdus asymbiotica*. *Emerging Infectious Diseases*. 12, 1562-1564.
- Glazer, I. 2002. Survival Biology. In: R. Gaugler (ed.), *Entomopathogenic Nematology*. CABI Publishing, Wallingford, Oxon, UK, pp. 169-187.
- Lawrence, J.L., Hoy, C.W., Grewal, P.S. 2006. Spatial and temporal distribution of endemic entomopathogenic nematodes in a heterogeneous vegetable production landscape. *Biological Control* 37: 247-255.
- Lewis, E.E. 2002. Behavioural Ecology. In: R. Gaugler (ed.), *Entomopathogenic Nematology*. CABI Publishing, Wallingford, Oxon, UK, pp. 205-223.
- Peel, M. M., D. A. Alfredson, J. G. Gerrad, J. M. Davis, J. M. Robson, R. J. McDougall, B. L. Scullie and R. J. Akhurst. 1999. Isolation, identification and molecular characterization of strains of *Photorhabdus luminescens* from infected humans in Australia. *J. Clin. Microbiol.* 37: 3647-3653.
- Peters, A. 1996. The natural host range of *Steinernema* and *Heterorhabditis* spp. and their impact on insect populations. *Biocontrol Science & Technology*. 6, 389-402.
- Shapiro-Ilan, D.I., Duncan, L.W., Lacey, L.A. and Han, R. 2005 Orchard Applications In: P.S. Grewal, R.-U. Ehlers and D.I. Shapiro-Ilan (eds), *Nematodes as biological control agents*. CABI Publishing, Oxfordshire, UK. pp. 215-229.
- Smits, P.H. 1996. Post-application persistence of entomopathogenic nematodes. *Biocontrol Science and Technology*. 6, 379-387.
- Susurluk, A. and R.-U. Ehlers 2005. Field persistence of the entomopathogenic nematode *Heterorhabditis bacteriophora* in different. *BioControl* 52, in press.

Appendix 4: Report from Small Group Meeting on current and future use of the EPPO List for IBCAs, held at CABI Europe-Switzerland, Delémont, Switzerland, March 11-12, 2007

This report was subsequently discussed and approved at the REBECA workshop in Frankfurt and final REBECA Conference in Brussels.

In attendance: Ulli Kuhlmann (chair), Andrea Raps, Miloslava Navratilova, Bernd Wührer, Karel Bolckmans, Richard Greatrex, and Emma Hunt.

The idea of listing IBCAs that are currently, or were at one time, widely used without any reports of adverse effects (positive list) was addressed by the European and Mediterranean Plant Protection Organization (EPPO). The first list for the EPPO region was published in 2002. The IBCAs are listed according to expert judgement of available information, and are related to certain criteria, such as: a) IBCAs are native or non-native, but established or widespread in the EPPO region, and successfully used in classical or inundative/inoculative biological control, b) IBCAs have been used for at least five years in at least five EPPO countries.

During the REBECA Meeting – Macrobiols – in Salzau in September 2006 the following comments and recommendations were made regarding to the existing EPPO List:

- The group supported the principle of the Positive List – access and use by industry, regulators and public;
- The current criteria require updating with additional information (distribution in EPPO region, countries that have approved/rejected licence, summary of ERA information etc);
- A system needs to be designed so issues of confidentiality do not arise;
- The status of list for use by regulators as an advisory tool needs clarification;
- EPPO 'endorsement' gives credibility.

In order to address the above-mentioned recommendations from Salzau, a small expert group was mandated to follow up in a meeting at CABI Delémont and to develop a proposal that will be presented and discussed further during the next meeting in Frankfurt at the beginning of July 2007.

During the meeting at CABI Delémont we discussed in detail the topics listed above as well as the following matters; criteria and format for inclusion of an IBCA on the EPPO List, reasons for removal from an EPPO list and the possibility of introducing

some geographical subdivisions of the EPPO region based upon climate. It should be noted that the small expert group took a pragmatic approach in consideration of the current situation that regulation of IBCAs is in place in some EU or EPPO countries, but not in others. As such, it is assumed that the decision-making process lies in the hands of the competent national regulatory authorities in each of the EU or EPPO countries where regulation is currently in place. At this meeting, the small expert group developed recommendations on how to proceed in countries where regulation is not in place and a new commercially or classical IBCA is being considered for release.

At the beginning of this meeting the potential benefits of an EPPO List for the national regulatory authorities were discussed.

Benefits of the EPPO List for Regulators:

- EPPO List can be used to verify the information given in the dossier;
- EPPO List provides additional valuable information, e.g on critical characteristics such as potential for establishment in warmer climates;
- EPPO list - if trustworthy – becomes a criterion for safety in the risk assessment.

Based on the discussions it became clear that not all national regulatory authorities are using the current EPPO List as an advisory tool because a revision is urgently needed.

At this point, the existing EPPO list accordingly specifies indigenous, introduced and established biological control agents which are recognized by the EPPO Panel on Safe Use of Biological Control to have been widely used in several EPPO countries. Based on this knowledge, other EPPO countries may therefore presume with some confidence that these agents can be introduced and used safely. They may, according to their judgement, dispense with, or simplify, the notification procedures proposed in the EPPO Standards PM6/1 and PM6/2. The agents are listed on the basis of expert judgement of available information.

In order to ensure that national regulatory authorities use the EPPO List as advisory tool the following recommendations to improve the existing EPPO List are suggested:

In the future, the revised EPPO List should divide IBCAs into the two following sections:

1. *Commercially used invertebrate biological control agents with history of safe use*, which are either indigenous and widespread in the EPPO region, or established and widespread in the EPPO region, or have been used for at least 5 years in at least 5 EPPO countries (exceptionally less, if crops are grown in few countries).
2. *Introduced classical invertebrate biological control agents*.

Data requirements for both sections of the EPPO List need to be revised as follows:

EPPO List, section 1; Commercially used IBCAs with history of safe use:

- Taxonomic classification (alternative names, synonyms, location of voucher specimens);
- Target pest (purpose of use);
- Use and extent of use (so far limited to indoor or outdoor use in existing list);
- Original distribution (country specific as far as possible);
- EPPO countries where used: approved/rejected, date of first use (some agents used but not necessarily officially approved);
- Distribution in EPPO: whether native or established and range of countries where established following release (draws distinction between area of use and area of establishment as a consequence of use. This is an important consideration for regulators because the potential for establishment in new countries or regions can be inferred from information on whether the species has established widely, or if it has a limited area of establishment);
- Potential for establishment (number of generations/year; development threshold temperature; or Europe versus Mediterranean; diapause characteristics - because they influence establishment);
- Host range;
- Additional remarks (e.g. special characteristics, such as flightlessness, which might affect establishment).

Consideration provided by regulators: Names of species no longer considered suitable for such a list remain on the list with details of why they have been withdrawn – this is essential information for any subsequent application for use of these particular species. Simple removal of a species from the list results in a loss of available information.

Obviously the existing EPPO List for commercially used IBCAs needs to be revised on the species level according to the requested additional information requirements (identity and taxonomic considerations/changes) by an expert group. The objective will be to identify and correct reported ‘errors’ on the list. Experts will include individuals considered to have relevant competence, such as (1) regulators; (2) biocontrol industry representatives; (3) taxonomists; and (4) other relevant experts.

EPPO List, section 2; Introduced classical IBCAs:

- Taxonomic classification (alternative names, synonyms, location of voucher specimens);
- Target pest and its original distribution

- Host plant of target pest
- EPPO countries where agent introduced
 - Information about establishment
 - Category of results
 - Single/multiple introductions
 - Date of introduction if available
- Distribution of agent within EPPO
 - Current status of spread to other countries after release of agent
 - Host plant of target pest
- Origin of agent (where collected)
 - Information on original distribution
- Host range
- Additional remarks
 - Information of adverse effects if available
 - Environmental risks if applicable
 - Provide key references and sources
 - Additional releases are not favoured based on new knowledge

A revision of the list by an expert group is needed, according to additional information requirements specified above. Information on countries and results of introduction will be updated based on information in the CABI BIOCAT database (data from 1900 to September 2006). Some EPPO countries will also provide published information. It should be noted that all introduced IBCAs of arthropods and weeds will be listed, therefore this list will become a comprehensive reference source for regulators. It is highly recommended that the CABI BIOCAT database be maintained since it is a valuable advisory tool for the regulatory process in the EPPO region and elsewhere. The CABI BIOCAT database has not been updated since September 2006 and REBECA needs to inform CABI about the valuable contribution such a database would make towards achieving future widespread use of the EPPO List as an advisory tool. The list of introduced classical IBCAs will be updated annually to include newly introduced species as well as any additional information for species already on the list. The expert group will consist of members who can offer the relevant expertise in classical biological control, such regulators with relevant competence, classical biological control practitioners and taxonomists.

Under the assumption that the existing EPPO List will be improved according to the recommendations, it is believed that the list will provide important baseline data about the safe use of commercially used IBCAs in EPPO member countries. The list will provide a standard that will facilitate the decision making process for national regulatory authorities within EPPO countries. The inclusion of a commercially used IBCA in the EPPO List should not lead to the automatic granting of permission to

release the IBCA on a wide scale but should become a criterion for safety in the risk assessment.

Recommendations concerning maintenance and use of the EPPO List:

The small expert group feels that there is not always sufficient knowledge available to national regulatory authorities for them to make a fair judgement on the environmental safety of IBCAs. In order to help national regulatory authorities with the evaluation of permit applications for new IBCAs, the small expert group strongly recommend the following:

- 1) Creation of an Expert Group on Environmental Safety of IBCAs (EGES), which can give non-binding advice on the environmental safety of new IBCAs;
- 2) Development of a Database on the Regulatory Status (DRS) of IBCAs to provide an overview of the regulatory status of new commercially used IBCAs in EPPO member states;
- 3) Development of a procedure for the transfer of commercially used IBCAs from the DRS onto the EPPO List after a critical review by the EGES.
- 4) Development of a procedure for the transfer of classical IBCAs onto EPPO List

Expert Group on Environmental Safety (EGES) of IBCAs

- A country that has no existing regulations for the introduction of new IBCAs may choose to seek advice from EGES on dossiers they receive. Countries that already have regulations in place but wish to have additional advice may also voluntarily send dossiers to EGES for feedback. Any recommendations given by EGES would be non-binding.
- The members and the necessary competence of EGES are yet to be defined, as are its terms of reference and affiliation to an international or EU organisation.

Database on the Regulatory Status of IBCAs (DRS)

- *Goal:* the goal of the DRS is to provide regulators with a database of information on the safety and regulatory status of new commercially used IBCAs that they could use in their decision making process.
- In order for an IBCA to be included in the DRS, one of the following is needed:
 - Positive recommendation by EGES for its use in at least one EPPO member country, or
 - An official release permit from at least one EPPO member country.
- The recommendation by EGES and the release permit by the national regulatory authority should always be based on critical evaluation of a permit application dossier and sufficient justification should be provided and included in the DRS.
- Information on rejected permit applications, including detailed justification for rejection, will also be placed in the DRS.

- The DRS will also include information on the use of IBCAs in countries that do not have a regulatory process in place yet. The advice of EGES can be requested for those countries.
- It was decided that at the present time it is not feasible to subdivide the EPPO region into different ecoregions. Therefore, to apply for inclusion of an IBCA on the DRS, separate applications will have to be submitted on a per country per IBCA basis.
- The DRS should be updated on a regular basis with information on new approvals.
- The DRS should contain the following fields:
 - Scientific name of IBCA
 - Name of applicant
 - Country
 - Regulatory process available in this country? (yes, no)
 - Regulatory status (submitted, approved, rejected, used)
 - Date of approval
 - Recommendation from the EGES
 - Link to the permit document
 - Information on observed adverse environmental effects
 - Contact person
- It is recommended that access to the DRS be restricted to regulators only (password protected) in order to protect the commercial interests of the biocontrol industry.
- It is recommended that IBCAs will be placed in the DRS per company. That is to say, when one company is successful in its application to include an IBCA in the database, this information will remain confidential for a period of five years (see below) such that all other companies or organisations will still have to submit their own dossiers and undergo the same application process to gain approval for the same IBCA.
- The DRS will be maintained by a host still to be defined, under the auspices of an independent international organisation such as EPPO, IOBC or another European organisation that is able to provide the necessary financial support.
- Benefits of the DRS for Regulators:
 - Network facility for competent national regulatory authorities;
 - Overview of regulatory status of IBCAs in Europe (EPPO, EU?);
 - Access to existing regulatory decisions and their justification;
 - Distribution tool for new information, e.g. on adverse environmental effects.

NOTE: until the database is available, a compendium of the national regulatory authorities including the internet addresses would be helpful to enable the collaboration of regulators.

Transfer from the DRS to the EPPO List of Commercially Used IBCAs with history of safe use.

- After a period of five years of inclusion on the database, the EGES will automatically critically review the environmental safety of an IBCA. New information on (adverse) environmental effects of the IBCA will be taken into account.
- Criteria for transfer to the EPPO List
 - At least 5 years inclusion in the database;
 - No new reports on adverse environmental effects;
 - A critical review of the environmental safety of the IBCA by EGES.
- An IBCA can be withdrawn from the EPPO List at any time. This may occur, for example, if new information becomes available pertaining to relevant adverse environmental effects of the IBCA. EGES would decide whether or not to remove the IBCA from the EPPO List based on critical evaluation of this information.
- Companies have the obligation to report new information about adverse environmental effects to EGES and national regulatory authorities.


Transfer from the DRS to the EPPO List of Classical Biological Control Agents

- After approval for introduction from one of the EPPO countries or a positive recommendation from EGES is received, the classical IBCA will be transferred directly from the DRS to the EPPO List
- Additional information on adverse environmental effects will be included on the EPPO List for Introduced Classical IBCAs if it becomes available.

NOTE: The EPPO List as it stands acts as only a database for introduction of classical IBCAs and even if there are indications of their environmental safety this does not have the same impact as the commercial IBCAs which are labelled with a history of safe use. There is no current mechanism to assess the safety of previously introduced classical IBCAs and this should be addressed in the future. It could be considered that section II of the list could be labelled “ Introduced Classical IBCAs with History of Safe Use”. This needs to be followed up in Frankfurt.

Please refer to flow-chart below.

Procedure for placing a new IBCA on the EPPO List



* Assessment documentation and reasons for acceptance or rejection included on database. Dossier not displayed.

DRS: Database on the Regulatory Status of IBCAs
 EGES: Expert Group on Environmental Safety of IBCAs
 IBCA: Invertebrate Biological Control Agent